Objective: To identify the minimal clinically important difference (MCID) for the Montgomery–
Asberg Depression Rating Scale (MADRS) in randomised studies of depression, and to …

Abstract The Montgomery–Asberg Depression Rating Scale (MADRS) is one of the most
commonly used symptom severity scales to evaluate the efficacy of antidepressant …

BACKGROUND: Time-and cost-effective self-rating scales of depressive symptoms are
particularly valuable for frequent use in large-scale effectiveness trials. The aim of the …

Abstract Background The use of Patient-reported Outcomes (PROs) as secondary endpoints
in the development of new antidepressants has grown in recent years. The objective of this …

Background Little is known about the clinical relevance of the Montgomery Asberg
Depression Rating Scale (MADRS) total scores. It is unclear how total scores translate into …

Abstract The Montgomery–Åsberg Depression Rating Scale (MADRS) is a widely used
clinician‐rated measure of depressive severity. Empirical support for the factor structure of …

Objective: In antidepressant efficacy trials, it is common to define treatment remission as a
score below a cutoff on symptom severity measures. No consensus has emerged regarding …

During the past decade the Montgomery–Asberg Depression Rating Scale (MADRS) has
been used with increasing frequency to measure outcome in antidepressant efficacy trials …

Background It has been claimed that efficacy estimates based on the Hamilton Depression
Rating-Scale (HDRS) underestimate antidepressants true treatment effects due to the …

The present study replicates a previous study in which we found that the less frequently
used Montgomery–Åsberg Depression Rating Scale (MADRS) is as sensitive an instrument …